Gefitinib (Iressa) for advanced non-small cell lung cancer.
D001682:Biological Availability; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy*; D018849:Controlled Clinical Trials as Topic; D003967:Diarrhea / Q000139:chemically induced; D004347:Drug Interactions; D066246:ErbB Receptors / Q000037:antagonists & inhibitors; D000077156:Gefitinib; D006207:Half-Life; D008175:Lung Neoplasms / Q000188:drug therapy*; D015337:Multicenter Studies as Topic; D011799:Quinazolines / Q000097:blood / Q000493:pharmacokinetics* / Q000627:therapeutic use*
D011799:Quinazolines; D066246:ErbB Receptors; D000077156:Gefitinib